NCCN 13th Annual Congress: Hematologic Malignancies™

New York, NY US
September 21, 2018 to September 22, 2018

The treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of new advances. In addition, targeted therapies and oral treatments bring new benefits to patients.

Agenda

Fees

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Summarize the current standards of oncology care and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and as appropriate integrate these strategies to optimize the management of patients with acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), Hodgkin lymphoma (HL), multiple myeloma (MM), myeloproliferative neoplasms (MPN), leukemia, lymphoma, and plasma cell neoplasms.
  • Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of patients with hematologic malignancies.
  • Review issues relevant to patients receiving CAR T-cell therapy, bone health and bone-related complications in patients with hematologic malignancies and incorporate appropriate strategies into clinical practice to improve patient outcomes.

A detailed list of learning objectives by session topic is available here.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Celgene Corporation
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • MEI Pharma
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
  • Pfizer
  • Sanofi Genzyme
  • Takeda Oncology

This activity is supported by independent educational grants from:

  • AbbVie
  • Incyte

This activity is supported by educational funding provided by Amgen.

This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 9.00 ABIM MOC
  • 9.00 ACPE contact hours
  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 ANCC contact hours
  • 9.00 Participation
Course opens: 
09/19/2018
Course expires: 
11/18/2018
Event starts: 
09/21/2018 - 6:00pm
Event ends: 
09/22/2018 - 5:00pm
Cost:
$0.00
New York Marriott Marquis
1535 Broadway
New York, NY 10036
United States

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Maintenance of Certification

This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Maintenance of Certification program. Successful completion of this CME activity enables the participant to earn up to 9 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Medical Specialties Maintenance of Certification
Through the American Board of Medical Specialties (“ABMS”) MOC Initiative to create a wide array of Maintenance of Certification (“MOC”) Activities through the ABMS MOC Directory, the NCCN 13th Annual Congress: Hematologic Malignancies™ has met the MOC requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:

MOC Part II CME Activity
Radiology

Note: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement (only). Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 9 hours of Category 1 credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 9 contact hours.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 9 contact hours (0.9 CEUs) of continuing education credit. UANs: 0836-0000-18-109-L01-P through 0836-0000-18-121-L01-P

Available Credit

  • 9.00 ABIM MOC
  • 9.00 ACPE contact hours
  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 ANCC contact hours
  • 9.00 Participation

Accreditation Period

Course opens: 
09/19/2018
Course expires: 
11/18/2018

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing